Nyxoah Launches Genio® Therapy in England

Nyxoah SA has announced the commercial launch of its Genio® system in England, marking a significant milestone for the company. The first patients were successfully implanted at University College London Hospitals (UCLH), as part of the NHS Specialised Services Devices Programme. This programme facilitates access to innovative therapies through specialized centers of excellence.

The Genio® system, used for treating Obstructive Sleep Apnea (OSA) via neuromodulation, was successfully implanted by Mr. Ryan Chin Taw Cheong, a consultant ENT and sleep surgeon at UCLH. Mr. Cheong expressed pride in offering this groundbreaking therapy to OSA patients. Nyxoah's CEO, Olivier Taelman, highlighted the importance of this milestone and expressed eagerness to expand collaborations with other hospitals in England.

The Genio® system, which is CE marked since 2019, represents a potential advancement in the field of sleep disorder treatments. Nyxoah aims to continue its mission of simplifying sleep for OSA patients worldwide.